ARTICLE | Clinical News
Polyphenon E fails actinic keratosis Phase II
July 2, 2005 12:49 AM UTC
MediGene (FSE:MDG) dropped EUR 2.25 (20%) to EUR 9 after its Polyphenon E ointment missed the primary endpoint of reduction in visible skin lesions in a Phase II trial to treat actinic keratosis. The ...